Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 iota-carrageenan studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 80% 1 394 Improvement, Studies, Patients Relative Risk, 95% CI RCTs 80% 1 394 Prophylaxis 80% 1 394 Iota-carrageenan for COVID-19 c19ic.com Nov 26, 2021 Favors iota-carrageenan Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 study c19ic.com Nov 26, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.11 Effect extraction pre-specified Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 Randomized Controlled Trials c19ic.com Nov 26, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.11 Effect extraction pre-specified Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 peer reviewed trials c19ic.com Nov 26, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.11 Effect extraction pre-specified Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control iota-carrageenan COVID-19 outcomes c19ic.com Nov 26, 2021 Favors iota-carrageenan Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit